Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2467${count})

  • Parkinson’s Disease Therapeutics Pipeline Program, 2025
    Assessing Pre-clinical Efficacy of Brain-penetrant TRPML1 Agonists to Treat Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) is characterized by the accumulation of misfolded and aggregated alpha-synuclein inside neurons in the brain. This may either arise from, or be exacerbated by...

  • MRI Biomarkers Program, 2025
    Evaluation of Neuromelanin-sensitive, Quantitative Susceptibility Mapping and Free Water Imaging as Biomarkers of Nigral Dopaminergic Dysfunction

    Study Rationale: This project seeks to validate three magnetic resonance imaging biomarkers capable of detecting and monitoring the degeneration of neurons in the substantia nigra in Parkinson’s...

  • Research Grant, 2025
    FUN-MITO: Functional Validation of Mitochondrial Polygenic Risk Scores in the PPMI Cohort

    Study Rationale: In the majority of people with Parkinson's disease (PWP), the movement disorder is not caused by mutations in a single gene. Until recently, these people were considered “sporadic”...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2025
    Pre-clinical Development of Novel GCase Variants for Treating Parkinson’s Disease

    Study Rationale: The most prevalent genetic risk factors for Parkinson’s Disease (PD) are mutations in GBA1, the gene that encodes the glucocerebrosidase (GCase) enzyme. Dysfunction of GCase leads to...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2025
    CT600 as a Neuroprotective Peptide Therapeutic for Parkinson’s Disease

    Study Rationale: Excess CDK5 protein kinase activity in the brain caused by the binding of CDK5 with another protein called P25 has been connected to Parkinson's disease. The CDK5-P25 interaction can...

  • MRI Biomarkers Program, 2025
    Validate Diffusion MRI Biomarkers of Early PD: A Multi-cohort Study of Free-water and CDM Measure

    Study Rationale: Parkinson’s disease and related synucleinopathies, such as Dementia with Lewy Bodies, are challenging to diagnose at their earliest stages due to subtle initial symptoms. Our research...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.